$78.34 0.46 (0.59%)
18:30 EDT PKI Stock Quote Delayed 20 Minutes
Previous Close $78.34
Market Cap 8.67B
PE Ratio 59.35
Volume (Avg. Vol.) 701,100
Day's Range 77.22 - 79.58
52-Week Range 62.91 - 102.46
Dividend & Yield 0.28 (0.36%)
PKI Stock Predictions, Articles, and PerkinElmer News
- From InvestorPlace
- From the Web
Expedia, Alexion and DowDuPont are just some of the stocks to buy to overcome the marketwide lethargy that takes shape this time of year.
These ten stocks are currently the most expensive stocks trading on the S&P 500 -- so buyer beware.
With a $8.1 billion market value, PerkinElmer Inc (NYSE:PKI) ranks in the top 25% of its industry group, Life Sciences Tools & Services, and in the top quarter of its sector group, Health Care, in market value. From the vantage point of investment attractiveness, Portfolio Grader's current ranking for PKI puts it 14 among the 31 companies in this industry group, putting it in the second quartile; in the top quartile of the sector with a ranking of 178 among the 782 companies in the sector, and number 956 in the nearly 5,000 company Portfolio Grader universe.
Currently, PerkinElmer Inc (NYSE:PKI) has a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. PKI has maintained this ranking for the last month.
PerkinElmer Inc (NYSE:PKI) is a constituent of the 32 company Life Sciences Tools & Services GICS industry group, which is part of the 781 company GICS Health Care sector. PKI has a market value of $8.0 billion which is in the top 25% of its industry group. Currently, the stock's Portfolio Grader ranking places it 7 among the 32 companies in this industry group, placing it among the leaders; in the top quartile of the sector with a ranking of 82 among the 781 companies in the sector, and number 512 in the nearly 5,000 company Portfolio Grader universe.
The current recommendation of Buy for PerkinElmer Inc (NYSE:PKI) is the result of using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing system. This represents no change from the previous week and is the same ranking PKI has had from Portfolio Grader for the last month.
Portfolio Grader currently ranks PerkinElmer Inc (NYSE:PKI) a Buy. With proprietary fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. PKI has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy.
Currently, PerkinElmer Inc (NYSE:PKI) has a Buy using Louis Navellier's Portfolio Grader stock evaluator, which incorporates his investing methodology. PKI has been upgraded from a Hold to a Buy in the last week.
Currently, PerkinElmer Inc (NYSE:PKI) has a Buy using Louis Navellier's system for investing and his Portfolio Grader stock evaluator. The shares have been upgraded from a Hold to a Buy in the last week.
PerkinElmer, Inc.’s (NYSE:PKI) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
From Simply Wall St
PerkinElmer (NYSE:PKI) has had a rough three months with its share price down 24%. However, stock prices are usually driven by a company’s financials over the long term, which in<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pki/perkinelmer/news/perkinelmer-inc-s-nysepki-fundamentals-look-pretty-strong-could-the-market-be-wrong-about-the-stock/">Read More...</a></div>
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), PerkinElmer (NYSE: PKI) and Nevro Crop (NYSE: NVRO)
From Analyst Ratings
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merck & Company (MRK – Research Report), PerkinElmer (PKI – Research Report) and Nevro Crop (NVRO – Research Report). Merck & Company (MRK) In a report released today, David Risinger from Morgan Stanley maintained a Buy rating on
Navellier RatingsPowered by Portfolio Grader